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c o r r e s p o n d e n c e
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Blood Pressure in Early Autosomal Dominant Polycystic 
Kidney Disease
To the Editor: In the Halt Progression of Poly-
cystic Kidney Disease (HALT-PKD) study, Schrier 
et al. (Dec. 11 issue)1 randomly assigned patients 
with early-stage autosomal dominant polycystic 
kidney disease (ADPKD) to either a standard 
blood-pressure target or a low blood-pressure 
target. The low blood-pressure target was associ-
ated with a slower increase in total kidney vol-
ume, but not with an overall change in the esti-
mated glomerular filtration rate (GFR). The latter 
finding might be viewed as being disappointing. 
However, we would caution that the institution 
of strict blood-pressure control will result in an 
acute, hemodynamic, but reversible decrease in 
the estimated GFR.
A recent scientific workshop sponsored by the 
U.S. National Kidney Foundation and the Food 
and Drug Administration concluded that this 
acute effect is not indicative of irreversible loss 
of nephrons.2 Accordingly, rather than using the 
baseline estimated GFR, we would suggest com-
paring only on-treatment slopes of the estimated 
GFR. Such an analysis does show a benefit as-
sociated with the low blood-pressure target 
(P = 0.05).1 Since a decrease in the estimated 
GFR is a late phenomenon in many patients with 
ADPKD,3 a subgroup analysis of on-treatment 
estimated GFR slopes with the use of forest 
plots would be of interest, since it might hint at 
whether certain subgroups of patients with early-
stage disease might benefit from a low blood-
pressure target.
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To the Editor: Schrier and colleagues evaluated 
aggressive blood-pressure control with the use of 
dual blockade of the renin–angiotensin system in 
patients with ADPKD. The study also has rele-
vance for physicians who initiated the use of such 
dual blockade in patients after it was reported 
that such treatment was more effective than sin-
gle blockade of the renin–angiotensin–aldoste-
rone system in reducing proteinuria.1
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Telmisartan Alone and in Combination with 
Ramipril Global Endpoint Trial (ONTARGET) 
and the Aliskiren Trial in Type 2 Diabetes Using 
Cardiorenal Endpoints (ALTITUDE) showed that 
dual blockade was not effective in reducing mor-
tality or morbidity from cardiovascular disease 
but rather was associated with more severe ad-
verse events such as hyperkalemia, hypotension, 
and acute kidney injury.2,3 A recent meta-analy-
sis therefore concluded that dual therapy should 
not be used.4
However, those studies included patients with 
a high preexisting risk of vascular events and 
death because of diabetes, cardiovascular disease, 
heart failure, or old age. In contrast, the study 
by Schrier et al. clearly showed that in a rela-
tively young population (15 to 49 years of age) 
without vascular disease, dual blockade was used 
relatively safely and that lowering blood pressure 
to values of 110/75 mm Hg did not result in ad-
verse effects. Thus, physicians who have success-
fully used dual blockade to reduce proteinuria in 
their patients may consider the continued use of 
such therapy in these patients.
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To the Editor: The HALT-PKD trial showed that 
in the low-blood-pressure group, as compared 
with the standard-blood-pressure group, the an-
nual increase in total kidney volume was sig-
nificantly less (5.6% vs. 6.6% increase per year). 
However, there was no benefit with regard to 
preservation of renal function. Blood-pressure 
goals were ambitious (95/60 to 110/75 mm Hg 
in the low-blood-pressure-group and 120/70 to 
130/80 mm Hg in the standard-blood-pressure 
group)1 in these young patients with ADPKD 
(mean age, 36.6 to 48.7 years). Current treatment 
guidelines of the European and U.S. Eighth Joint 
National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pres-
sure do not support the use of such low blood-
pressure targets in patients with nonproteinuric 
or even proteinuric chronic kidney disease, but 
instead they suggest blood-pressure targets lower 
than 140/90 mm Hg in all patients. The European 
Society of Cardiology guidelines support blood-
pressure targets lower than 130 mm Hg in pa-
tients with chronic kidney disease and overt pro-
teinuria.2,3 Blood-pressure goals that are as low 
as those defined by the HALT-PKD trial investi-
gators may be dangerous in elderly patients with 
chronic kidney disease, presumably because of 
the high burden of prevalent cardiovascular dis-
ease in these patients. Similarly, in a very large 
cohort study involving 651,749 U.S. veterans with 
chronic kidney disease,4 the optimal blood-pres-
sure range was reported to be 130 to 149 mm Hg 
systolic pressure and 70 to 89 mm Hg diastolic 
pressure, and mortality increased markedly with 
blood-pressure levels lower than 120/80 mm Hg.
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The Author Replies: Messchendorp and Ganse-
voort raise the issue of using only on-treatment 
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estimated GFR slopes to evaluate the benefit of 
therapy. In our study, patients in the low-blood-
pressure group, as compared with patients in the 
standard-blood-pressure group, had a slower 
increase in total kidney volume (P = 0.006), a 
greater reduction in the left-ventricular-mass index 
(P<0.001), and reduced urinary albumin excretion 
(P<0.001). We also agree that the on-treatment 
slope of the estimated GFR shows a benefit for 
the low blood-pressure group (P = 0.05).
In patients with chronic kidney disease such 
as ADPKD, the degree of proteinuria is a risk 
factor for cardiovascular complications and a 
decrease in kidney function. Thus, Wetzels’s 
point is valid in that dual renin–angiotensin 
blockade may be indicated if it is shown to 
lower urinary protein excretion significantly more 
than monotherapy and is safe. Such may be the 
case in younger patients with ADPKD.
We agree with Benck et al. that aiming for 
blood pressure of less than 120/80 mm Hg may 
not be advisable in patients with chronic kidney 
disease, particularly in elderly patients. However, 
among patients with chronic kidney disease who 
have type 2 diabetes, those with blood pressure 
lower than 130/80 mm Hg have fewer complica-
tions and longer survival than those with blood 
pressure lower than 140/90 mm Hg.1
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Atenolol versus Losartan in Marfan’s Syndrome
To the Editor: Lacro et al. (Nov. 27 issue)1 re-
port no benefit of losartan, an angiotensin- 
receptor blocker (ARB), over the beta-blocker 
atenolol in respect to the rate of aortic-root dila-
tation in Marfan’s syndrome. A possible interpre-
tation of this study might be that ARBs are as 
effective as beta-blockers in the treatment of pa-
tients with Marfan’s syndrome.2 However, such 
an interpretation assumes that beta-blockers are 
an effective treatment option.
Beta-blockers are presently considered to be 
first-line therapy in patients with Marfan’s syn-
drome. However, their benefit is debatable and 
not supported by robust evidence. Several obser-
vational studies and only one clinical trial3 have 
evaluated the effectiveness of beta-blockers in 
patients with Marfan’s syndrome, and the re-
sults have been conflicting. Two meta-analyses 
also reached opposing conclusions4,5 (Table 1). 
Remarkably, no study showed a benefit of beta-
blockers in preventing clinical end points (e.g., 
death or dissection).
As a reflection of these uncertainties, the 
2010 guidelines of the American College of Car-
diology Foundation and the American Heart As-
sociation recommend the use of beta-blockers, 
whereas the 2014 guidelines of the European 
Society of Cardiology do not. If beta-blockers are 
not truly effective, then the study by Lacro et al. 
has really shown that ARBs are as effective as a 
placebo.
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